SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to treating ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of ...

The others have Type 2 diabetes and often administer insulin via multiple daily injections (MDI). “We have been successful in driving innovation and adoption of CGM in the Type 1 diabetes community, ...

Dexcom Inc. revealed data from several studies showing significant benefits of its continuous glucose monitoring technology on adults with type 2 diabetes who are not treated with insulin. In one ...

A new survey from Dexcom suggests that living with Type 2 diabetes can have significant impacts not only on physical health but on mental health, too. The diabetes devicemaker conducted the survey ...

In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

Alberta Government is now covering Dexcom G7, providing eligible residents living with either type 1 or type 2 diabetes with increased access to the life-changing technology Alberta residents living ...